Canaccord Genuity Comments on Momenta Pharmaceuticals (MNTA)

Article Stock Quotes (1) Comments (0)

Canaccord Genuity maintained a Hold rating on Momenta Pharmaceuticals (NASDAQ: MNTA) and their price target of $12.00.

Analysts noted a lack of near-term catalysts, but think long-term catalysts
potential remains.

"M-enox revenues are a modest royalty stream, and M356 generic Copaxone launch is delayed until 2016. While MNTA's Baxter-partnered biosimilars program and branded drugs have significant long-term potential, lack of near-term catalysts may limit 12-month upside. Our $12 target is based on sum-of-the-parts analysis."

For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.

Shares of Momenta Pharmaceuticals closed at $13.77 yesterday, with a 52 week range of $10.15-$19.64.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Needham & Company Lifts Numbers on Marvell (MRVL) on Solid Results
• Deutsche Bank Resumes CenterPoint Energy (CNP) at Hold
• Williams-Sonoma (WSM) Delivers 'Clean' Q1 Beat - Analyst

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Canaccord Genuity

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?